证券代码：300239 证券简称：东宝生物 包头东宝生物技术股份有限公司投资者关系活动记录表 编号：2015-02 | --- | --- | --- | |-----------------|--------------------------------|------------------------------------------------------------------| | | | | | 投资者关系活 | ■特定对象调研 □分析师会议 | | | 动类别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称 | | 上海豪丰投资发展中心（有限合作）投资总监任建龙先生、杭州峥战投资 | | 及人员姓名 | | 管理有限公司总经理、投资总监孙占军先生 | | 时间 | 2015 年 05 月 27 | 日下午 15:30-17:30 | | 地点 | 东宝生物办公楼会议室 | | | 上市公司接待 | | 董事会秘书、副总经理刘芳、证券事务代表元向荣、证券投资部高 ...

证券代码：300239 证券简称：东宝生物 编号：2015-01 投资者关系活 ■特定对象调研 □分析师会议 动类别 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称 华泰证券：研究所医药行业研究员肖汉山、包头市东河区证券营业部马笑 包头东宝生物技术股份有限公司投资者关系活动记录表 及人员姓名 菊总经理、北京分公司包头钢铁大街证券营业部刘军营销总监 | --- | --- | |--------------|-----------------------------------------------------------------------| | 时间 | 2015 年 03 月 26 日下午 15:00-16:30 | | 地点 | 东宝生物董秘办公室 | | 上市公司接待 | 董事会秘书、副总经理刘芳、证券事务代表元向荣、证券投资部高级经理 | | 人员姓名 | 单华夷 | | | 一、 2014 年公司库存增加的原因？ | | | 公司库存的增加主要是 2014 年受明胶市场回落以及下游客户 GMP 认 | | 投资者关系活 | 证 ...

参与单位名称 华泰证券研究所医药行业研究员肖汉山先生、华泰证券包头市东河区证券 及人员姓名 营业部总经理马笑菊女士、长富汇银投资基金管理有限公司投资副总裁高 士珂先生、中国信达资产管理股份有限公司内蒙分公司高级经理助理韩波 先生、内蒙古大学 EMBA 中心主任李鹏先生 上市公司接待 董事长王军、董事会秘书、副总经理刘芳、财务总监赵秀梅、证券事务代 人员姓名 表元向荣 证券代码：300239 证券简称：东宝生物 包头东宝生物技术股份有限公司投资者关系活动记录表 编号：2015-03 | --- | --- | --- | --- | |--------------|------------------------|---------------------------------|-------| | | | | | | 投资者关系活 | | ■特定对象调研 □分析师会议 | | | 动类别 | □媒体采访 □业绩说明会 | | | | | □ 新闻发布会 □路演活动 | | | | | □现场参观 | | | | | □ | 其他 （请文字说明其他活动内容） | | 时间 2015 年 6 月 8 日上午 1 ...

参与单位名称 中信建投证券股份有限公司研究发展部首席食品饮料/农林牧渔行业分析 及人员姓名 师黄付生、中信建投证券股份有限公司研究发展部高级经理/农林牧渔行 业分析师许奇峰、包商银行食品与农业金融事业部行业研究员张晋溢 时间 2016 年 2 月 17 日 15：00- 16：30 地点 东宝生物办公楼会议室 上市公司接待 董事会秘书刘芳、技术总监王富荣、证券部高级经理单华夷 人员姓名 一、公司目前明胶产能 6500 吨，未来将扩产到 10000 吨，公司怎么 看明胶市场？ 答： 投资者关系活 明胶分为骨明胶和皮明胶。公司目前主营骨明胶。主要产品有"金 动主要内容介 鹿"牌胶囊用明胶、食品添加剂明胶。 绍 明胶市场发展趋势： 证券代码：300239 证券简称：东宝生物 包头东宝生物技术股份有限公司投资者关系活动记录表 编号：2016-01 | --- | --- | --- | --- | |--------------|------------------------|---------------------------------|-------| | | | | | | 投资者关系活 | | ■特定对 ...

证券代码：300239 证券简称：东宝生物 编号：2017-001 包头东宝生物技术股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | ■ | 特定对象调研 □分析师会议 | | | □ 媒体采访 □业绩说明会 | | | 投资者关系 | □ 新闻发布会 □路演活动 | | | 活动类别 | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称 | | 国泰君安 孙金钜 吴璋怡 杨萍 刘佳 | | 及人员姓名 | | 深圳清水源投资管理有限公司 蔡秋斌 | | | | 中铁宝盈资产管理有限 ...

编号：2022-003 证券代码：300239 证券简称：东宝生物 包头东宝生物技术股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |-------------------------|---------------|----------|-----------------------------------------------------------------------------| | | 特定对象调研 | | 分析师会议 | | 投资者关系活动 | □媒体采访 | | 业绩说明会 | | 类别 | □新闻发布会 | | □路演活动 | | | □现场参观 | | | | | 其他 ( | 电话会议 | ) | | | 长城证券 | 黄淑妍 | | | | 银河基金 | 李 | | | 参与单位名称及 人员姓名 | 广发资管 | 刘 | | | | 华富基金 | 陈 | | | | 建银理财 | 施伟锋 | | | 时间 | 2022 年 6 | 月 17 | 16:00 — 17:00 | | 地点 | 线上交流 | | | | 上市公司接待人 | | | ...

证券代码：300239 证券简称：东宝生物 包头东宝生物技术股份有限公司 投资者关系活动记录表 编号：2022-002 | --- | --- | --- | |-------------------------|------------------------------------|-------------------------------------------------------------------| | | 特定对象调研 | 分析师会议 | | 投资者关系活动 | □媒体采访 | 业绩说明会 | | 类别 | □新闻发布会 | □路演活动 | | | □现场参观 | | | | 其他 2022 | "股东来了"走进上市公司——东宝生物 | | 参与单位名称及 人员姓名 | 恒泰证券及个人投资者共 | 15 人； | | 时间 | 2022 年 6 月 15 日 | 09:00-11:00 | | | | | | 地点 | 东宝生物生态园区研发中心一楼会议室 | | | 上市公司接待人 | | 副总经理、董事会秘书单华夷；证券业务主管倪帆 | | 员姓名 | | | | | 一、参观东宝生 ...

证券代码：300239 证券简称：东宝生物 包头东宝生物技术股份有限公司 投资者关系活动记录表 编号：2022-004 | --- | --- | --- | |----------------|------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------| | | 特定对象调研 | 分析师会议 | | 投资者关系活动 | □媒体采访 | 业绩说明会 | | 类别 | □新闻发布会 | □路演活动 | | | □现场参观 | | | | 其他 ( 电话会议 ) | | | | 长城证券 刘 鹏 | | | 参与单位名称及 | 长城证券 黄淑妍 | | | 人员姓名 | 东方基金 杨贵宾 | | | | 建信基金 郑丁源 | | | 时间 | 2022 年 11 月 8 日 15 ： | 30-16:30 | | 地点 ...

Financial Performance - The company's revenue for Q3 2022 reached ¥229,684,681.49, representing a 69.39% increase year-over-year[5] - Net profit attributable to shareholders was ¥29,809,651.68, a significant increase of 381.33% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥27,672,248.86, up 479.52% year-over-year[5] - The basic earnings per share for the period was ¥0.0502, reflecting a 321.85% increase compared to the same quarter last year[5] - The company's operating revenue for Q3 2022 reached ¥706,043,743.51, an increase of 71.26% compared to ¥412,267,239.59 in the same period last year[12] - Operating profit for the quarter was ¥107,490,911.86, compared to ¥17,011,668.55 in the previous year, reflecting a substantial growth[31] - The net profit for the third quarter of 2022 was ¥92,439,092.18, a significant increase from ¥13,670,658.88 in the same period last year, representing a growth of approximately 576%[32] - The net profit attributable to shareholders of the parent company was ¥87,784,562.99, compared to ¥13,744,660.50 in the previous year, indicating a year-over-year increase of about 537%[32] - The basic and diluted earnings per share for the third quarter were both ¥0.1479, up from ¥0.0248 in the prior year, reflecting an increase of approximately 497%[32] Assets and Liabilities - Total assets as of September 30, 2022, amounted to ¥2,219,279,610.42, a 5.07% increase from the end of the previous year[5] - Total liabilities decreased to ¥486,400,284.44 from ¥508,580,671.06, showing improved financial stability[29] - The company's equity attributable to shareholders increased to ¥1,506,877,799.19 from ¥1,422,692,834.57, reflecting a growth of 5.9%[29] - Current assets totaled ¥971,578,588.47, an increase of 8.8% from ¥892,592,899.38[29] - Non-current assets rose to ¥1,247,701,021.95, compared to ¥1,219,647,603.86 at the start of the year[29] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥126,730,842.75, showing a 401.86% increase[5] - The net cash flow from operating activities increased significantly by 401.86% to ¥126,730,842.75, compared to ¥25,252,201.87 in the previous year[13] - Cash inflow from sales of goods and services was ¥496,962,022.72, compared to ¥249,580,843.04 in the previous year, indicating an increase of about 99.4%[34] - The net cash flow from financing activities was ¥127,868,845.94, down from ¥254,532,800.08 in the same period last year, reflecting a decrease of about 50%[36] - The company reported cash outflows from investing activities totaling ¥167,582,255.61, a decrease from ¥334,263,088.04 in the previous year, showing a reduction of approximately 50%[35] Research and Development - R&D expenses surged by 149.80% to ¥17,057,544.09, up from ¥6,828,546.10, driven by increased investment in research and the inclusion of Yiqing Bio in the consolidated financial statements[12] - Research and development expenses for the quarter were ¥17,057,544.09, significantly higher than ¥6,828,546.10 in the same period last year, indicating a focus on innovation[31] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 23,574, with no preferred shareholders[15] - The top shareholder, Qingdao Guoen Technology Co., Ltd., holds 21.18% of the shares, amounting to 125,711,022 shares[15] Other Financial Metrics - The company reported a significant increase in contract liabilities, which rose by 40.54% to ¥6,741,472.07, indicating higher prepayments from customers[10] - The income tax expense rose dramatically by 362.14% to ¥15,439,361.35, up from ¥3,340,873.70, due to increased profits[12] - The company experienced a significant increase in other income, which rose by 2376.26% to ¥642,902.56, compared to ¥25,962.63 in the previous year[12] - The company reported a net loss from investments of ¥718,952.78, an improvement of 57.09% from a loss of ¥1,675,448.37 in the prior period[12] Corporate Developments - The company completed the employee stock ownership plan, enhancing employee cohesion and corporate culture[21][22] - The company successfully increased capital for its subsidiary Yiqing Bio, completing the industrial and commercial change registration[23] - The company established two new subsidiaries to advance its multi-point terminal business strategy and launched new products including collagen peptide drinks and enzyme powders[25] - The company is actively developing e-commerce live streaming to promote star products and strengthen terminal operations[25] - The company optimized raw material procurement and production efficiency, contributing to improved operational performance[20] - The company merged with its subsidiary Yiqing Bio, resulting in increased sales revenue and profit[20] Audit and Reporting - The third quarter report was not audited, indicating that the figures presented are preliminary and subject to change[37]

Financial Performance - The company's operating revenue for the reporting period was ¥476,359,062.02, representing a 72.18% increase compared to ¥276,670,413.54 in the same period last year[26]. - Net profit attributable to shareholders reached ¥57,974,911.31, a significant increase of 667.73% from ¥7,551,503.43 year-on-year[26]. - The net profit after deducting non-recurring gains and losses was ¥55,403,889.73, up 3,096.24% from ¥1,733,408.58 in the previous year[26]. - The net cash flow from operating activities was ¥108,230,931.16, a remarkable increase of 1,721.51% compared to -¥6,674,707.77 in the same period last year[26]. - Basic and diluted earnings per share were both ¥0.0977, reflecting a 588.03% increase from ¥0.0142[26]. - Total assets at the end of the reporting period were ¥2,187,662,627.21, a 3.57% increase from ¥2,112,240,503.24 at the end of the previous year[26]. - The company's revenue for the reporting period reached ¥476,359,062.02, representing a year-on-year increase of 72.18% due to steady growth in gelatin and collagen product sales[86]. - The operating costs increased to ¥352,976,047.34, a rise of 44.44% compared to the previous year, primarily driven by the increase in revenue[87]. - Research and development expenses surged by 121.01% to ¥20,242,699.19, reflecting the company's commitment to innovation and the inclusion of its subsidiary Yiqing Bio's R&D costs[87]. Market and Industry Trends - The company operates in the biopharmaceutical and health industry, which is a strategic emerging industry encouraged by national policies[34]. - The collagen protein application areas include health food, functional food, cosmetics, and industrial applications, with a projected CAGR of 6.55% for the health food market from 2020 to 2025[37]. - The overall market sales are improving, benefiting the health market's sustained and stable development[37]. - The retail sales of consumer goods in China decreased by 11.1% year-on-year, but in June, it turned positive with a growth of 3.1% year-on-year and 0.53% month-on-month, benefiting the company's product promotion and brand building[38]. - The collagen market is in a rapid development phase, with increasing applications in pharmaceuticals, food and beverages, and cosmetics, presenting growth opportunities for the company[40]. Product Development and Innovation - The company plans to launch a new gelatin product by the end of the year and is expecting clinical approval for its hemostatic materials project[35]. - The company has launched multiple new products in 2022 and established new channels and platforms to enhance its market presence[40]. - New retail products launched in 2022 include collagen peptide powders and various health supplements, catering to diverse consumer needs[51]. - The company is committed to research and development of new products, including functional fertilizers and plant growth stimulants, to support modern agricultural development[49]. - The company launched a series of new products in 2022, including collagen peptide powder and probiotics, aiming to establish a breakthrough in terminal business[62]. - The company is focusing on optimizing production processes and reducing costs while developing high-value-added new products[68]. Strategic Acquisitions and Partnerships - The company has strengthened its core competitiveness and industry leadership by acquiring Yiqing Bio, extending its industrial chain[39]. - Yiqing Bio, a subsidiary, has initiated a new intelligent industrialization project for hollow capsules to meet the growing demand in the pharmaceutical and health product markets[41]. - The company is actively collaborating with high-quality production enterprises to expedite the market launch of the "Yuan Su" series of new products[71]. Marketing and Brand Development - The company has appointed a celebrity spokesperson to boost brand awareness and has implemented diverse promotional strategies[62]. - The company aims to enhance its market influence and increase market share through comprehensive brand promotion strategies[128]. - The company is focusing on building a strong domestic collagen brand, "Yuan Su," to capture a larger market share[128]. Environmental and Social Responsibility - The company is committed to low-carbon green manufacturing, aligning with national strategic planning to reduce carbon emissions[70]. - The company has established an environmental protection management committee and has implemented a comprehensive environmental monitoring plan[141]. - The company actively participates in social responsibility initiatives, contributing over 200,000 yuan in products to aid pandemic relief efforts[144]. Governance and Compliance - The company emphasizes the protection of investor rights and has improved its information disclosure practices[143]. - The company has committed to avoiding unfair related-party transactions, ensuring transparency and fairness in all dealings[149]. - The company has established a governance structure that allows for independent operation and decision-making by its board and management[149]. Future Outlook - The company provided an optimistic outlook for the second half of 2022, projecting a revenue growth of 25% based on current market trends and product demand[152]. - Future guidance indicates a focus on sustainability initiatives, with plans to reduce carbon emissions by 25% over the next three years[152].